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Abstract Few areas of recent research have received as
much focus or generated as much excitement and debate as
stem cell research. Hope for the therapeutic promise of this
field has been matched by social concern associated largely
with the sources of stem cells and their uses. This interplay
between promise and controversy has contributed to the
enormous variation that exists among the environments in
which stem cell research is conducted throughout the
world. This variation is layered upon intra-jurisdictional
policies that are also often complex and in flux, resulting in
what we term a ‘patchwork of patchworks’. This patchwork
of patchworks and its implications will become increasingly
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important as we enter this new era of stem cell research.
The current progression towards translational and clinical
research among international collaborators serves as a
catalyst for identifying potential policy conflict and makes
it imperative to address jurisdictional variability in stem cell
research environments. The existing patchworks seen in
contemporary stem cell research environments provide a
valuable opportunity to consider how variations in regu-
lations and policies across and within jurisdictions influ-
ence research efficiencies and directions. In one sense, the
stem cell research context can be viewed as a living
experiment occurring across the globe. The lessons to be
gleaned from examining this field have great potential for
broad-ranging general science policy application.
Keywords Stem cell research . Policy . Regulation .
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Introduction
Few areas of recent research have received as much focus
or generated as much excitement and debate as stem cell
research. It has captured the attention of policymakers, the
popular press, funding agencies, patient groups and the
general public. Hopes regarding the therapeutic promise of
this field are countered by social concerns associated
largely with the sources of stem cells and their uses. This
interplay between promise and controversy has contributed
to the enormous variation that exists among the environ-
ments in which stem cell research is conducted in different
jurisdictions around the world. Such variation is layered
upon intra-jurisdictional policies that are also often com-
plex and in flux. The resulting multifaceted and, at times,
overlapping and discordant regimes present both within and
between different jurisdictions constitute what we term a
‘patchwork of patchworks’.
This patchwork of patchworks and its implications are
increasingly important in light of a number of strong
indications that we are entering a new era in the field of
stem cell research. New sources of stem cells and stem cell
research technologies are emerging including, among
others, induced pluripotent stem cells and interspecies
somatic cell nuclear transfer. These research tools hold
great promise for enlarging the frontiers of biological
understandings and advancing drug development, while
also raising fresh ethical and legal concerns [1–3]. Further,
new clinical advances are coming to the fore, novel funding
sources are emerging, and political landscapes in some
jurisdictions, most notably the United States (U.S.) [4], are
being transformed, raising the possibility that major
changes in research and funding policies will result.
Importantly, the U.S. Food and Drug Administration
(FDA) recently issued its first approval for clinical trials
using the products of human embryonic stem cells [5]. In
addition, these developments are occurring in the midst of a
world-wide economic crisis in which efficiency is particu-
larly important and competition for resources is increasing.
This current progression towards translational and
clinical research among international collaborators serves
as a catalyst for identifying potential policy conflict and
makes it imperative to address jurisdictional variability in
stem cell research environments. Doing so necessitates
analyzing the variables relevant to this area of research
and considering the influence of this variability on
research and its downstream application, so as to gather
knowledge and understandings that will provide the tools
necessary to navigate these complexities effectively. It will
be important to pursue these ends in a manner that
respects different cultural, social and religious norms and
values, while encouraging the realization of the potential
social benefits of stem cell research.
Stem cell research is not unique in its complexity. There are
many areas of research with jurisdictional variations (e.g.
genomics and genetically modified organisms). However, the
existing patchworks seen in contemporary stem cell research
environments appear particularly acute. Given the tremendous
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commitment to this area of research shown by the scientific
community, policy makers and funders, and the level of
excitement it engenders in the public, it provides a valuable
opportunity to consider how variations in regulations and
policies across and within jurisdictions influence research
efficiencies and directions. In one sense, the stem cell research
context can be viewed as a living experiment occurring across
the globe and the lessons to be gleaned from examining this
developing field have great potential for broad-ranging
general science policy application.
In order to initiate this complex analysis, we gathered an
international group of scholars from a variety of disciplines
with the dual purposes of forming a picture of the current
lay of the land of the international stem cell research
environment, and of identifying key areas requiring further
investigation.1 The research presented in the papers
accompanying this introductory piece provided the ground-
work for this initiative.2 These supporting papers address a
number of key areas of study including public perceptions
regarding stem cell sources and policies, international
policy interoperability and harmonization in stem cell
research, perspectives of scientists and researchers regardi
ng the ethical issues of stem cell research, and the themes
currently emerging in discourse surrounding stem cell
research. This research served to inform the initial
exploration presented here, and will provide the foundation
for ensuing examination and analysis.
A Complex Patchwork
It has been widely noted that there are clear and profound
differences in how jurisdictions regulate stem cell research
[6, 7] (see Side Bar). Some countries permit human
embryonic stem cell research (hESC) with imported lines
only and prohibit the derivation of new hESC lines from
excess IVF embryos and somatic cell nuclear transfer
(SCNT) (e.g. Germany & Italy). Some jurisdictions permit
both (e.g., the United Kingdom (“U.K.”)), while others
prohibit both (e.g., Ireland). Other countries permit hESC
research and the derivation of new hESC lines from
supernumerary IVF embryos, but prohibit SCNT (e.g.,
Denmark & Canada). Some nations (e.g., Argentina) have
no laws explicitly governing hESC research, while others
have significant variation within their borders. Consider, for
example, the patchwork of regulations that has emerged
within the U.S., where states differ dramatically on various
regulatory issues regarding hESC research including the
procurement of gametes, embryos, and other cells from
human donors, the derivation of new hESC lines, and the
use(s) of these lines [8]. In addition to these types of
policies, there are many other forms of variation that add to
the complexity of the patchwork.
Public perception of stem cell research varies widely
around the world. Given the plurality of religious and
cultural norms that often inform positions on stem cell
research globally [9], this variance is to be expected.
Research shows that the derivation of stem cells from
certain sources has served as a flashpoint for controversy
and debate, particularly around the use of human embryos.
A recent comparison of nine European countries found a
plurality of perceptions on embryo research, ranging from
the view that human embryos have the same status as live
human beings (e.g., Austria and Germany), to the view that
human embryos in their earliest stages are not yet
sufficiently developed to constitute individual human
entities (e.g., Denmark and the U.K.) [10]. SCNT, while
receiving less research attention, has been shown to elicit
greater resistance among U.S. [11] and U.K. publics [12]
than has hESC research.
Public views are moderated by worldviews including
attitudes and trust toward science, scientists and regulatory
institutions, religiosity, media use, and gender, among other
factors [13–15]. While public opinion patterns seem
broadly suggestive of policy directions [16], and at times
are implicated in policy making discourse [17], there is
little evidence to date that policy preferences are directly
linked to public views and the role public opinion plays in
the policy making process varies considerably. In some
cases, policy makers explicitly use public opinion to inform
their decision making processes - for example, the U.K.’s
Human Fertilisation and Embryology Authority’s public
consultation on hybrids and chimeras [18] - but in others,
there is apparent discrepancy between public opinion and
policy. Further research is required to illuminate the
relationship between public opinion, policy and science
reality across jurisdictions.
Patent policy provides an excellent example of variance
as the role and appropriateness of strong patent legislation
in the biotechnology field remains subject to debate [19–
21]. Nonetheless, industry—especially biotech and phar-
maceutical corporations—research funding agencies, gov-
ernments and other entities often view patents as an
essential element of the commercialization process and as
a key factor in promoting innovation and economic
stimulus [22, 23]. In the area of stem cell research, there
is significant international variation in what is deemed
patentable. In the U.S., embryonic stem cell lines are
clearly patentable (e.g., Thomson, J.A. U.S. Patent No.
1 The international workshop, “Lay of the Land”, took place in
Montreal, PC on January 15–16, 2009, as part of a Stem Cell Network
funded project, “The Stem Cell Research Environment: Drawing the
Evidence and Experience Together”.
2 A condensed version of this article, entitled “International stem cell
environments: a world of difference”, was published in Nature Reviews
Stem Cells, online: 16 April 2009 | doi:10.1038/stemcells.2009.61.
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5,843,780 (1998); Thomson, J.A. U.S. Patent No.
6,200,806 (2001)) [24]. Conversely, the European Patent
Office recently came to the opposite conclusion and refused
to grant a patent covering the use of hESC, using the public
order and morality grounds [25]. In other jurisdictions (e.g.,
Canada) the future of embryonic stem cell research patents
is less clear. The impact these differing patent policies will
have on research remains uncertain and will require on-
going monitoring.
The funding of stem cell research and the focus on
commercialization also varies by jurisdiction. In some
jurisdictions, such as Singapore and California, stem cell
research is part of a special state-sponsored economic and
scientific platform and its funding is part of a specific strategic
initiative [26]. In others, research in the area is primarily
supported through science funding mechanisms typical of the
jurisdiction such as government funding, granting agencies
and foundations (e.g., U.K. and Canada). In some jurisdic-
tions, namely parts of the U.S., there is limited funding
available through the traditional sources (i.e. federal granting
agencies), and it comes with limitations. Arguably, various
dynamics are implicated in these differing approaches
including economic, political and social variables.
Many other factors add to the complexity of this story of
variation in research environments. There are jurisdictional
differences in clinical trial regulations including the use of
biologics, privacy rules, informed consent and assessment
of risk. Research ethics norms associated with donation of
embryos and tissues vary between jurisdictions and at times
are undefined, influx or developing within given jurisdic-
tions [27, 28]. Relevant research practice standards,
including both research conduct and technical standards
relating to cell line derivation and maintenance, are not
universal. Another factor that cannot be overlooked relates
to jurisdictional research capacity which is increasingly
important as the field becomes more technologically
complex. Clinical trial capacity and industry receptor
capacity also significantly impact the nature and extent of
the research being conducted. Finally, the capacity of
different health care systems to respond to clinical develop-
ments and to address issues of access and social justice
must be considered. Variation in all of these areas is
reflective of both policy and funding factors.
It must be noted that there are a number of emerging
recommendations and policy activities occurring at both
national and international levels (e.g., the International
Society for Stem Cell Research (ISSCR); the Interstate
Alliance (U.S.), and the UNESCO Statement) that are part
of an effort to promote greater harmonization in regula-
tions, coordinate the ethical review of stem cell lines and
materials, and promote transparency and enforcement of
existing regulations. Nevertheless, different understandings
regarding core values and principles endure between (and
amongst) policy makers, civil society representatives and
researchers. At times, these differences lead to disagree-
ments, fragmentation or uncertainty about what constitutes
appropriate conduct in different jurisdictions and settings.
Influence and Relevance of the Patchwork
While the data are still emerging, it seems axiomatic that
the variability outlined above will impact the research
environment. However, the nature of this impact remains
undetermined and is why systematic analyses of the
different variations, both individually and in combination,
are critical. Even within jurisdictions, many of the variables
are often in flux which can make it particularly challenging
to trace impact and make connections. Given the number of
elements that might be at work in any given context, an
added conundrum is identifying and measuring the specific
influential factors and their respective impact(s).
Divergent research environments, particularly policy
frameworks and governing regulations, inevitably affect
the conduct of stem cell research, including procurement,
derivation, banking, distribution and use of stem cell lines.
Variability arguably has the potential to introduce ineffi-
ciencies related to the sharing of materials and data and to
the production of research. It may inhibit collaboration at
both national and international levels, and restrict the flow
of research and researchers [29]. It is also likely to have an
impact on clinical translation. For example, concerns about
past histories of various stem cell lines because of differing
consent standards—in the absence of grandfathering
clauses—could cause reticence by some institutions and/or
researchers to use some lines [30]. Moreover, policy
variations regarding the use of monetary payments for the
donation of human reproductive materials and other ethical
standards may also hinder research. For instance, several
jurisdictions prohibit the importation of gametes and stem
cell lines that have not been procured in accordance with
local regulations [31]. Accordingly, a line derived through
an egg sharing procurement arrangement in the U.K. may
not be eligible for study using California Institute of
Regenerative Medicine funding. A key challenge in
addressing such policy variability is to identify what degree
of consistency is required for effective cooperation, and
what mechanisms can be used to manage differences.
Actors in one jurisdiction may recognize a policy adopted
in another as being substantially equivalent provided that it
complies with certain basic principles, even if some
differences remain. On other matters, they might demand
strict policy convergence. Identifying clear and transparent
rules will facilitate more efficient research conduct.
The nature of the international stem cell research
environment patchwork also provides an opportunity to
Stem Cell Rev and Rep (2009) 5:82–88 85
explore the impact of different research environments and
policies on scientific productivity. For example, do permis-
sive regulatory approaches translate to increased produc-
tivity, or is this connection overstated? There is tentative
evidence that policy variation may impact research outputs
[32, 33]. However, more nuanced research is required to
illuminate the prevalent factors. Another key issue is what
impact intellectual property protections have on innovation
and collaboration [34]. At the present time, it is challenging
for researchers to assess whether patents encourage or
discourage innovation globally [35, 36]. However, focusing
specifically on the stem cell patent patchwork, it is possible
to develop accurate patent landscapes [37] and to identify
the more visible hurdles [38, 39] raised by patenting laws
and practices, in order to inform future policy decisions.
These different regimes present scholars of innovation with
a sort of laboratory for studying the impact of the
regulatory environment on research and development.
In addition to its impact on productivity and efficiency, the
patchwork is also associated with potential human and ethical
costs. Stem cell tourism, where often desperate patients seek
treatment or participation in ‘medical innovations’ outside of
clinical trials in jurisdictions with lax regulations for human
subjects research, thereby exposing themselves to significant
physical and financial risk, serves as a particularly concerning
illustration of these costs. This issue has recently received
international attention [40, 41]. When combined with ‘forum
shopping’ by researchers who move to jurisdictions where
they can work in a less regulated manner [42], these real but
avoidable harms to patients may also impede the progress of
stem cell science. International efforts are necessary to
address this issue, particularly given that some jurisdictions
simply do not have the capacity to implement FDA-style
regulation. The movement of scientists and research workers
(including trainees) across international borders also raises
the issue of ethics education—or what might be labeled
ethics re-orientation of migrant scientists. While these efforts
require resources, they may also stimulate the cross-cultural
comparison of norms. The intersection between the interna-
tional science ethos and local ethical cultures makes studying
different ways of providing ethical education to researchers a
matter of some significance.
Notwithstanding the foregoing issues, as stem cell
research is a controversial area that engages various ethical,
religious, intellectual, social and cultural beliefs, some
degree of variation in policy and perspective is clearly
healthy and inevitable. Further, plurality invites innovative
approaches and unique perspectives, and permits balance
between extremes. The current patchwork is potentially
responsible for the pursuit of different technologies, diverse
training and varied discoveries. It also reflects the broad
diversity of opinion and belief evident between people
around the world and, at times, encourages novel collabo-
rations (both scientific and political) and unlikely partner-
ships. As such, the existence of a patchwork is not
necessarily detrimental. In addition, given the many
underlying norms at play in this area there are some issues,
including those such as the moral status of the embryo,
patenting human biological material, and ethical issues
surrounding gamete donation, on which agreement is
unlikely.
However, in other areas such as research standards, clinical
readiness, cell line quality and scientific integrity, policy
uniformity appears more attainable and beneficial. The
International Stem Cell Banking Initiative, the ISSCR’s
Registry of Provenance of Human Embryonic Stem Cell
Lines and the European Commission’s European Human
Embryonic Stem Cell Registry serve as examples of efforts to
promote international cooperation for research and clinical
purposes [43]. The varying opportunities to find common
ground on particular issues can be viewed on a continuum of
flexibility, as represented in Fig. 1. Adopting this approach
permits focused consideration of the areas most likely to
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(e.g.) The International Stem Cell Banking Initiative, the
ISSCR’s Registry of Provenance of Human Embryonic Stem
Cell Lines & the European Commission’s European Human
Embryonic Stem Cell Registry are initiatives that promote
availability of information and international cooperation.
Harmonization Attempt
(e.g.) The United Nation’s treaty banning human cloning
failed to achieve consensus and instead, the General
Assembly adopted the (non-binding) United Nations








Fig. 1 Continuum of flexibility
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Conclusion
While data regarding the impact of variation in research
contexts is still emerging, at a minimum it seems safe to say
that the story is more complex than is often expressed and
cannot be reduced to the permissiveness or restrictiveness of
any given jurisdiction(s) [44]. Factors including, but not
limited to, jurisdictional capacities, funding and commercial-
ization policies, patent policy, research ethics, technical
standards, public opinion, and social norms all have an
impact on the stem cell research environment. The resulting
implications will affect the development of clinical knowl-
edge, scientific talent, fundamental knowledge, and research
tools, but further analysis is necessary to determine the
nature and quality of that impact. When there has been such
extensive investment in an area of research, as there has been
with stem cell research—financially, politically and in the
hopes of patients—and yet little clinical realization of this
potential promise to date, it seems essential that we examine
the factors driving the development of this area so that we
are better positioned to enhance its future progress.
Recognizing and then examining the current patchwork
of patchworks evident in the stem cell research environ-
ment also provides an opportunity to assess the impact of
science policy and social context generally, with a view to
informing the future direction of policy development and to
improving efficiency and interoperability, where appropri-
ate. One of the potential benefits of improving on the
inefficiencies resulting from policy variance may be to
assist stakeholders to benefit from new knowledge and
scientific innovation in a more timely manner, which is a
natural aim of therapeutically focused scientific research.
We are not the first group to note these complexities [45],
nor do we purport to have all the answers. This article, and
the research published alongside it, will encourage further
thought, analysis and investigation into the various issues
raised by the patchwork of patchworks and will serve as a
basis for a more broadly based and fruitful discourse, and
for further investigative study.
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Side Bar  A Case Study: Australia, Canada & the United Kingdom – three similar countries
with stark policy variations
The complexity of the story underlying stem cell research policy is particularly acute in 
the stark policy variations evident in the legislative approaches adopted by Australia,
Canada and the U.K. to SCNT and interspecies somatic cell nuclear transfer (iSCNT). 
The main difference between both technologies is the source of ova which acts as a
receptacle for the nucleus of the somatic cell – human ova in SCNT, and animal ova in 
iSCNT. In Australia, iSCNT is prohibited but SCNT is permitted; in Canada the
converse is likely true, while in the U.K. both are allowed. These three nations are
culturally similar jurisdictions with comparable political systems and religious
backgrounds, and yet they have arrived at very different policy standpoints on these
contentious issues. The question is why?
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